Search Results for "Aziza Othmana W Kip Dia"

08:50 EST 24th November 2014 | BioPortfolio

Matching Channels

None

Matching News

Corporate Governance Developments at BIOASTER, Institute for Technology Research in Health.

Philippe ARCHINARD, President of Lyonbiopôle, replaces Alain MÉRIEUX as President of BIOASTER. He will also fulfill executive responsibilities conferred by his role as President of B...

Genclis SAS Coordinate a Roundtable in a Molecular Allergology Seminar

Nancy, France, November 20, 2014 - Genclis, a molecular diagnostic company in the fields of allergy and cancer, will attend the 2nd French Molecular Allergology Seminar in Paris on November 22 ...

VECT-HORUS appoints Dr Jamal Temsamani as Director of Drug Development & Corporate

Marseille, October 30, 2014 - VECT-HORUS, a biotechnology company that designs and develops peptide vectors facilitating the delivery of drugs or imaging agents, notably in the brain, announced ...

Genclis SAS Releases First Data for Severidia® Molecular Diagnostic in Triple-Negative Breast Cancer

Nancy, France, October 29, 2014 - Genclis, a molecular diagnostic company in the fields of allergy and cancer, announced today the presentation of the first clinical data for its molecular ...

INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER

INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER AND MEMBER OF THE EXECUTIVE COMMITTEE Marcel Rozencweig becomes President of Innate Pharma Inc., based in the US  Marseille, Sep...

INNATE PHARMA : IPH4102 PRECLINICAL DATA PUBLISHED IN "CANCER RESEARCH"

IPH4102 is a first-in-class anti-KIR3DL2 monoclonal antibody in development for the treatment of cutaneous T-cell lymphoma (CTCL). Phase I trial is expected to start in 2015 IPH4102 shows p...

INNATE PHARMA : INITIATION OF A PHASE I CLINICAL TRIAL OF LIRILUMAB IN COMBINATION WITH ELOTUZUMAB

Initiation of a PHASE i clinical trial OF lirilumab IN COMBINATION WITH elotuzumab This Phase I trial will test the safety and tolerability of lirilumab (BMS-986015) in combination with elo...

INNATE PHARMA: Third DSMB for EffiKIR trial recommends continuation as planned

Marseille, France, September 25, 2014   Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibo...

Matching PubMed Articles

None

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement